By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Genomic Health, Inc. 

301 Penobscot Drive

Redwood City  California  94063  U.S.A.
Phone: 650-556-9300 Fax: 650-556-1132


SEARCH JOBS

Genomic Health, Inc. (NASDAQ: GHDX) is the world's leading provider of genomic-based diagnostic tests that address both the overtreatment and optimal treatment of early-stage cancer, one of the greatest issues in healthcare today. The Oncotype DX® portfolio of breast, colon and prostate cancer tests applies advanced genomic science to reveal the unique biology of a tumor in order to optimize cancer treatment decisions. With half a million patients tested in more than 70 countries, the Oncotype DX tests have redefined personalized medicine by making genomics a critical part of cancer diagnosis and treatment. Based in Redwood City, Calif. with European headquarters in Geneva, Switzerland, the company is applying its world-class scientific and commercial expertise and infrastructure to lead the translation of genomic data into clinically-actionable results for treatment planning throughout the cancer patient's journey.


Key Statistics


Email:
Ownership: Public

Web Site: Genomic Health, Inc.
Employees:
Symbol: GHDX
 



Industry
Medical Device






Company News
Genomic Health, Inc. (GHDX): New Oncotype DX® Data Presented At 2014 San Antonio Breast Cancer Symposium Further Demonstrate The Practice-Changing Impact Of The Test In Guiding The Treatment Of Early Stage Breast Cancer 12/15/2014 10:12:45 AM
Genomic Health, Inc. (GHDX) Release: Oncotype DX DCIS Score Represents Breakthrough In Personalizing Treatment Of Pre-Invasive Breast Cancer 12/12/2014 8:07:14 AM
Genomic Health, Inc. (GHDX) Announces Presentation Of First Prospective Outcomes Study Of Oncotype DX Breast Cancer Test 12/10/2014 8:35:17 AM
Genomic Health, Inc. (GHDX) Advances Development Of Novel Liquid Biopsy-Based Cancer Tests 12/9/2014 11:29:32 AM
Genomic Health, Inc. (GHDX) Release: Oncotype DX Predicts Outcomes In Prostate Cancer Patients, Significantly Changes Treatment Recommendations 12/3/2014 11:51:26 AM
Genomic Health, Inc. (GHDX) To Present At The 26th Annual Piper Jaffray Healthcare Conference 12/1/2014 3:50:35 PM
Genomic Health, Inc. (GHDX) Release: Results from Second Oncotype DX Prostate Cancer Test Clinical Validation And First Decision Impact Study To Be Published In European Urology And Urology Practice, Respectively 11/19/2014 12:26:52 PM
Genomic Health, Inc. (GHDX) Announces Third Quarter 2014 Financial Results And Reports Continued Growth In U.S. Invasive Breast Cancer Business 11/5/2014 7:36:08 AM
Genomic Health, Inc. (GHDX) To Present At The Credit Suisse Annual Healthcare Conference 11/4/2014 9:07:29 AM
Genomic Health, Inc. (GHDX) To Announce Third Quarter 2014 Financial Results And Host Conference Call On Tuesday, November 4, 2014 10/28/2014 7:59:26 AM
12345678910...
//-->